June 16, 20223 min read, 575 words
Published: June 16, 2022 | 3 min read, 575 words
×Bygene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat children early enough to prevent...
CRITIC REVIEWS
There don't seem to be any reviews yet.
PUBLIC REVIEWS
Great Context
June 16, 2022
I think this is well sourced and the context allows the reader to take the win and still understand what needs to be pushed and aided in order for this win to actually help more people. A little information on how the new science works, but more information on why the treatment is so expensive.
June 16, 2022
Great Context
July 1, 2022
This CRISPR treatment is amazing, the way the author explains may seem simple, "just re-coding the cell" but the process this scientist must have gone through is hard. Stem cells are a real wonder, and I hope they manage to make these alterations while inside the patient like they believe they will one day.
July 1, 2022
Great Context
June 25, 2022
It is nice to read a story and see successful results that might improve the lives of people with painful, debilitating diseases. When I was young, an old neighbor with Sickle Cell Anemia asked me, "Do you know why they call it sick as hell anemia? Because it makes you sick as hell." To think that pain like what she described could be remedied is happy news. The content includes potential side effects that might be difficult to live with as well as the high expense that might hinder access.
June 25, 2022
Great Context
June 16, 2022
Fantastic reporting that does an excellent job of explaining in simple language the current state of the technology and its application in early trials for treating beta thalassaemia and sickle cell disease. Great read.
June 16, 2022